Log In
Print
BCIQ
Print
Print this Print this
 

AD04

  Manage Alerts
Collapse Summary General Information
Company ADial Pharmaceuticals LLC
DescriptionUltra low-dose formulation of ondansetron, a generic serotonin (5-HT3) receptor antagonist
Molecular Target Serotonin (5-HT3) receptor
Mechanism of ActionSerotonin (5-HT3) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationAddiction
Indication DetailsTreat alcohol use disorder
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1.8M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today